COMMUNIQUÉS West-GlobeNewswire

Chemed Corporation Announces a Five-Year $450 Million Amended and Restated Credit Agreement
13/04/2026
CINCINNATI, April 13, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation ("Chemed") (NYSE:CHE) announced that it has entered into an Amended and Restated Credit Agreement for its Credit Facility (“Credit Agreement”). JPMorgan [...]
Microbot Medical® Commences Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System in the U.S. at the Society of Interventional Radiology (SIR) Annual Scientific Meeting
13/04/2026
Successful Execution of the Limited Market Release (LMR) Includes Adoption by Globally Recognized Healthcare Systems in the U.S. Market and Demonstrates Broad Market Scalability in Key Endovascular Procedures HINGHAM, [...]
Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism
13/04/2026
Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-479 in Healthy Volunteers Data Anticipated in Late 2026 or Early 2027 SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE [...]
Optum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse Practitioners
13/04/2026
Policy Update Broadens Access to Innovative, Non-Drug Depression Treatment Across 26 States and Washington, D.C. MALVERN, Pa., April 13, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology [...]
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
13/04/2026
AKB-9090 is being evaluated as a potential treatment for cardiac surgery-associated acute kidney injury CAMBRIDGE, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a [...]
BrainsWay to Participate in the 25th Annual Needham Virtual Healthcare Conference
13/04/2026
BURLINGTON, Mass. and JERUSALEM, April 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental [...]
Veld Pharmaceuticals GmbH Announces Collaboration with Chiesi Farmaceutici S.p.A to Expand Access to Rare Disease Therapies Across Africa
13/04/2026
Managed Access Program to support physician-led access to nine rare-disease therapies in accordance with local regulatory frameworks ZUG, Switzerland, April 13, 2026 (GLOBE NEWSWIRE) -- Veld Pharmaceuticals GmbH (“Veld [...]
Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
13/04/2026
Mackay Base Hospital activated March 31, 2026 as first clinical trial site; first patient dosed within days of activation — a signal of strong enrollment velocity and significant unmet medical need SARASOTA, Fla., April [...]
ImPact Biotech Presents Preliminary Data from Phase 1 Study of Padeliporfin VTP in LA-PDAC at SIR 2026 and Provides Strategic Business Update
13/04/2026
– Initial data from first cohort in LA-PDAC show 66% (2/3) patients resected following VTP at lowest light dose with a consistent and well-tolerated safety profile – – LA-PDAC program represents large market opportunity [...]
Neomorph Announces Closing of $100 Million Series B Financing
13/04/2026
Financing will support the ongoing Phase 1/2 trial of NEO-811 for the treatment of locally advanced or metastatic non-resectable clear cell renal cell carcinoma (ccRCC) and the continued advancement of the company’s [...]
Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary
13/04/2026
Tim is a seasoned legal executive bringing extensive experience supporting commercial biopharmaceutical companies FOSTER CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial- [...]
Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement
13/04/2026
Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement Peer-reviewed consensus redefines debridement from simple tissue removal to a more comprehensive biologically active [...]
Eclipse Life Sciences Completes Enrollment in Phase 2 Study Evaluating EC-104 for Diabetic Macular Edema (DME)
13/04/2026
RESEARCH TRIANGLE PARK, N.C., April 13, 2026 (GLOBE NEWSWIRE) -- Eclipse Life Sciences, Inc., a privately held clinical-stage biopharmaceutical company focused on the development of novel therapies for ophthalmic [...]
Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences
13/04/2026
VICTORIA, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference
13/04/2026
-Trial Combines LIXTE’s LB-100 with Dostarlimab; Results Give Patients New Hope for a Challenging Disease with Limited Therapeutic Options- BOCA RATON, Fla., April 13, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology [...]
Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures
13/04/2026
-- Select findings demonstrate that the use of EXPAREL ® (bupivacaine liposome injectable suspension) in outpatient Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) is associated with lower total [...]
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
13/04/2026
SPY001 met its primary endpoint with a statistically significant reduction of 9.2 points (p<0.0001) from baseline at Week 12 in Robart’s Histopathology Index (RHI) score Secondary endpoints included clinical [...]
Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD
13/04/2026
New SOL-1 post-hoc analyses presented at VBS reinforce AXPAXLI’s unmatched durability in wet AMD with sustained disease control AXPAXLI demonstrated robust CSFT control with a median time of 39 weeks and 46 weeks to ≥ [...]
OXB launches fast-track offering for AAV and lentiviral vector platforms, accelerating viral vector development and manufacture
13/04/2026
New expedited service line designed for biotechs with timeline constraints, launched in response to client demand Can accelerate timeline to GMP manufacturing by up to nine months, driven by key innovations and [...]

Pages